Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department

NCT ID: NCT03467672

Last Updated: 2019-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-23

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several studies have described the interest of eosinopenia as a marker of infection in internal medicine or in intensive care units. Eosinopenia is an inexpensive and easily accessible biological marker of sepsis. Retrospective work in the adult emergency departments of Strasbourg University Hospitals has shown the good specificity of this biological sign for the diagnosis of infection. Our work aims to confirm the results by a more meaningful study.

Main objective: Evaluation of the interest of eosinopenia in the diagnosis of bacterial infection in ED.

Methodology: inclusion of all patients with criteria for bacterial infection in ED, inclusion of an equivalent number of uninfected control patients.

Duration : 12 months Multicentric prospective study 6 centers : Strasbourg, Hôpital Nord Franche comté, Sélestat, Wissembourg, Colmar, Mulhouse

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infected patients

Diagnosis of bacterial infection

Intervention Type OTHER

use of eosinopenia in the diagnosis of bacterial infection

Control group

Diagnosis of bacterial infection

Intervention Type OTHER

use of eosinopenia in the diagnosis of bacterial infection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnosis of bacterial infection

use of eosinopenia in the diagnosis of bacterial infection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* major patient
* patient suspected of infection and benefiting from the routine practice of NFS, whatever the indication during his / her visit to the emergency room.
* patient with or without criteria for bacterial infection
* patient affiliated to a social security scheme
* patient (or legal representative) who has agreed to participate in the study

Exclusion Criteria

* anti tumor chemotherapy
* immunosuppressive treatment
* corticotherapy
* antibiotherapy in progress
* malignant hemopathy
* evolutionary cancer
* refusal to participate in the study
* subjects under safeguard of justice
* subject under guardianship or curatorship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CH de COLMAR

Colmar, , France

Site Status RECRUITING

CH de MULHOUSE

Mulhouse, , France

Site Status RECRUITING

Ch Selestat

Sélestat, , France

Site Status RECRUITING

Les Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status RECRUITING

CH Nord Franche comte

Trévenans, , France

Site Status RECRUITING

Ch Wissembourg

Wissembourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Charles-Eric Dr. LAVOIGNET

Role: CONTACT

03 84 98 33 97

Pascal BILBAULT

Role: CONTACT

03 88 12 86 82

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sophie PINCEMAILLE-CHAMPION

Role: primary

03 89 12 40 00

Jacques SCHMITT

Role: primary

03 88 64 64 64

Laura BEJINARIU

Role: primary

03 88 57 55 55

Charles-Eric LAVOIGNET

Role: primary

03 84 98 33 97

Pascal BILBAULT

Role: backup

03 88 12 86 82

Charles-Eric LAVOIGNET

Role: primary

03 84 98 33 97

Hakim SLIMANI

Role: backup

03 84 98 34 11

Fanny SCHWEITZER

Role: primary

03 88 54 11 11

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6228

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.